Stock 4506 SUMITOMO PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-05 am EDT 		5-day change 1st Jan Change
404 JPY -0.74% Intraday chart for Sumitomo Pharma Co., Ltd. -0.25% -13.30%
Jul. 02 Inovio Pharmaceuticals Names Steven Egge Chief Commercial Officer MT
Jul. 02 INOVIO Appointsof Steven Egge as Chief Commercial Officer CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Inovio Pharmaceuticals Names Steven Egge Chief Commercial Officer
MT
INOVIO Appointsof Steven Egge as Chief Commercial Officer
CI
Sumitomo Pharma : Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress
PU
Sumitomo Pharma : Announces Organizational Realignment and Changes in the Positions Assumed by Executive Officer and Other Key Positions
PU
Sumitomo Pharma : Posted Conference on FY2023 Financial Results
PU
Sumitomo Chemical Co., Ltd. - Announcement of Finance Income, Restructuring Costs, and Extraordinary Loss in Non-consolidated Financial Statements
AQ
Sumitomo Pharma : May 14, 2024 Conference on FY2023 (April 1, 2023 to March 31, 2024) Financial Results
PU
Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024
Sumitomo Pharma : Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including Representative Directors, Executive Officer, and the Positions Assumed by Executive Officers
PU
Sumitomo Pharma : Presentation Material (Conference on FY2023 Financial Results)
PU
Sumitomo Pharma : Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate
PU
Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
CI
Sumitomo Pharma Co., Ltd. Announces No Dividend for the Year Ended March 31, 2024
CI
Sumitomo Pharma : Notice of Company Split (Simplified Absorption-type Company Split) of the Frontier Business and Notice of Business Acquisition by a Wholly-Owned Subsidiary of the Company
PU
Sumitomo Pharma : Notice of Company Split (Simplified Absorption type Company Split) of the Frontier Business and Notice of Business Acquisition by a Wholly Owned Subsidiary of the Company
PU
Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.
CI
Profit-Taking, China Outlooks Churn Asian Stock Markets
MT
Sumitomo Pharma : Posted Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024
PU
Sumitomo Pharma : May 01, 2024 Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024 transcript
PU
Fed Outlook, Earnings Season Roil Asian Stock Markets
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4506 Stock
  4. News Sumitomo Pharma Co., Ltd.